The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus.
Concentrations of the terminal complement complex (TCC), C5b-9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2-year period during active and inactive phases of the disease. In 9 of the 11 patients, elevations in TCC concentrations correlated with disease exacerbations. In many of these patients, C3 and C4 levels remained normal during the study and were less sensitive indicators of disease activity than were TCC concentrations. We believe that measurements of TCC are useful in monitoring patients with rheumatic diseases in which complement activation is a component.
Gawryl
M S
MS
Department of Immunology/Microbiology, Rush-Presbyterian-St. Luke's Chicago 60612.
Chudwin
D S
DS
Langlois
P F
PF
Lint
T F
TF
D000328:Adult; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage
D003176:Complement C3; D003181:Complement C4; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins; D011241:Prednisone